Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials.
Journal article
Voysey M. et al, (2023), Clin Exp Immunol
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Journal article
Feng S. et al, (2021), Nature Medicine
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.
Journal article
Swanson PA. et al, (2021), Sci Transl Med, 13
Highly-Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe Polymerase Chain Reaction
Preprint
Ratcliff J. et al, (2021)
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Journal article
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
Divergent trajectories of antiviral memory after SARS-Cov-2 infection
Preprint
Tomic* A. et al, (2021)
Antibody evasion by the P.1 strain of SARS-CoV-2.
Journal article
Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Journal article
Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Journal article
Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Journal article
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.
Journal article
Townsend A. et al, (2021), Nat Commun, 12
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
Journal article
Emary KRW. et al, (2021), SSRN Electronic Journal
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
Journal article
Voysey M. et al, (2021), The Lancet
Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers
Preprint
Barton A. et al, (2021)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.
Journal article
Andersson MI. et al, (2020), Wellcome open research, 5, 181 - 181
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Journal article
Folegatti PM. et al, (2020), Lancet, 396, 467 - 478
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel.
Journal article
Ainsworth M. et al, (2020), Wellcome open research, 5, 139 - 139
SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus
Journal article
Andersson MI. et al, (2020)
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.
Internet publication
Valente Pinto M. et al, (2020), 7